BioTuesdays

Tag - Bradley Canino

Theseus-Logo
Markets

Stifel starts Theseus Pharma at buy; PT $24

Stifel initiated coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and $24 price target. The stock closed at $7.35 on March 15. Theseus is a clinical-stage, small molecule oncology company that...

March 16, 2023
Deciphera Pharma
Markets

Stifel cuts Deciphera Pharma to hold; PT to $10 from $60

Stifel downgraded Deciphera Pharmaceuticals (NASDAQ:DCPH) to “hold” from “buy” and slashed its price target to $10 from $60 after the failure of the company’s Qinlock in 2L gastrointestinal stromal tumor (GIST).  Shares...

November 8, 2021
Affimed
Markets

Stifel starts Affimed at buy; PT $12

Stifel launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and price target of $12. The stock closed at $5.85 on Sept. 29. Affimed is a clinical-stage biotechnology company focused on bispecific antibody...

September 30, 2021